Related Experiment Video

Updated: Jun 4, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Development of second-generation VEGFR tyrosine kinase inhibitors: current status

Pankaj Bhargava1, Murray O Robinson

  • 1AVEO Pharmaceuticals, Inc., 75 Sidney Street, 4th floor, Cambridge, MA 02139, USA. pbhargava@aveopharma.com

Current Oncology Reports
|February 15, 2011
PubMed

Insights

Targeting vascular endothelial growth factor receptors (VEGFRs) is crucial for cancer treatment, especially in renal cell carcinoma (RCC). Newer, more selective VEGFR inhibitors offer improved potency and fewer side effects than older drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Vascular Endothelial Growth Factor (VEGF) signaling drives tumor angiogenesis and is critical in renal cell carcinoma (RCC) due to pathway deregulation.
  • Current treatments for advanced RCC utilize multi-targeted tyrosine kinase inhibitors (TKIs) like sorafenib, sunitinib, and pazopanib, which inhibit VEGFRs but also off-target kinases, leading to adverse effects.
  • The need for more effective and safer cancer therapies necessitates exploring novel therapeutic strategies targeting VEGF signaling.

Purpose of the Study:

  • To review recent advancements in the development of second-generation VEGFR TKIs.
  • To focus on the potential benefits of novel inhibitors with enhanced potency and selectivity for VEGFRs.
  • To provide an overview of targeted therapies for renal cell carcinoma.

Main Methods:

  • Review of recent scientific literature and clinical trial data on VEGFR inhibitors.
  • Analysis of the selectivity and potency profiles of existing and novel VEGFR TKIs.
  • Examination of the role of VEGF signaling in renal cell carcinoma pathogenesis.

Main Results:

  • Second-generation VEGFR TKIs, such as tivozanib and axitinib, demonstrate improved selectivity for VEGFRs compared to first-generation TKIs.
  • Novel inhibitors are being developed with the aim of achieving greater potency and specificity in blocking VEGF signaling.
  • Enhanced selectivity may lead to a better adverse effect profile and improved therapeutic outcomes in cancer patients.

Conclusions:

  • Targeting the VEGF pathway remains a validated strategy for cancer treatment, particularly for renal cell carcinoma.
  • Next-generation VEGFR TKIs offer the potential for improved efficacy and tolerability by increasing selectivity and potency.
  • Further research into novel inhibitors with optimized selectivity is warranted to advance cancer therapy.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...